GnRH analogues, which also down-regulate FSH and LH release, decrease prostate size and are thus commonly used for treatment of benign prostate hypertrophy in dogs [48] and humans [49], and prostate cancer cancer in humans [50]. Here, BRD2 is linked to benign prostatic hyperplasia.